Latest news with #HyosungHeavyIndustries
Korea Herald
30-05-2025
- Business
- Korea Herald
Energy Storage MoU Signed Between REPT BATTRO and Hyosung Heavy Industries
SHANGHAI, May 30, 2025 /PRNewswire/ -- On May 27, 2025, REPT BATTERO and Hyosung Heavy Industries formally signed a Memorandum of Understanding (MoU) in Seoul, South Korea, focusing on battery energy storage systems. REPT BATTERO will supply 2.5GWh of energy storage products, jointly promoting the application and popularization of energy storage technology in the global market. Centered on establishing a global strategic framework for energy storage, REPT BATTERO will deliver energy storage cells, modules, and DC containers to Hyosung Heavy Industries, while providing technical support for system design integration and quality control. Hyosung Heavy Industries will assume responsibilities for global marketing, regional localization, and regulatory certification. Through the 2.5GWh supply partnership, both entities seek to progressively establish a dominant position in the global energy storage market, underpinning their commitment to advancing scalable and sustainable energy solutions worldwide. Woo Tae-hee, the CEO & President of Hyosung Heavy Industries stated, "Hyosung Heavy Industries is dedicated to becoming a global leader in energy solutions, and this collaboration will further solidify our market positions in the energy storage sector. We will closely collaborate with REPT BATTERO to deliver innovative products and services to global customers." Feng Ting, the CEO & President of REPT BATTERO remarked, "This signing marks a significant breakthrough in market synergy between Chinese and South Korean energy storage enterprises. As a global leading battery technology supplier, REPT BATTERO's high-efficiency energy storage batteries complement Hyosung Heavy Industries' deep expertise in the global power industry. Through deep cooperation, the two sides will provide professional products and services to more overseas customers." REPT BATTRO and Hyosung Heavy Industries affirmed their commitment to building upon this strategic partnership to strengthen collaboration in international markets, collectively tackle climate change challenges, and contribute Chinese and Korean insights and solutions to the global energy transition. About Hyosung Heavy Industries Hyosung Heavy Industries, founded in 1977, is a leading Korean company recognized for its global competitiveness in high- and ultra-high-voltage power equipment and energy infrastructure. Hyosung commands the No.1 market share for power transformers in Korea, holds approximately 40% share in the domestic low-voltage motor market, and has accumulated more than KRW 10 trillion in circuit breaker salesboth locally and globally. In Europe, Hyosung leads the 400kV transformer market, especially in Norway with over 80% market share. With decades of EPC experience and strong system engineering capabilities, Hyosung Heavy Industries supplies high-reliability power systems to the Middle East, Southeast Asia, the Americas, and Europe. By addressing global trends toward decarbonization, decentralization, and digitalization in the energy sector, the company is positioning itself as a key enabler of sustainable, global energy transformation.
Yahoo
30-05-2025
- Business
- Yahoo
Energy Storage MoU Signed Between REPT BATTRO and Hyosung Heavy Industries
SHANGHAI, May 30, 2025 /PRNewswire/ -- On May 27, 2025, REPT BATTERO and Hyosung Heavy Industries formally signed a Memorandum of Understanding (MoU) in Seoul, South Korea, focusing on battery energy storage systems. REPT BATTERO will supply 2.5GWh of energy storage products, jointly promoting the application and popularization of energy storage technology in the global market. Centered on establishing a global strategic framework for energy storage, REPT BATTERO will deliver energy storage cells, modules, and DC containers to Hyosung Heavy Industries, while providing technical support for system design integration and quality control. Hyosung Heavy Industries will assume responsibilities for global marketing, regional localization, and regulatory certification. Through the 2.5GWh supply partnership, both entities seek to progressively establish a dominant position in the global energy storage market, underpinning their commitment to advancing scalable and sustainable energy solutions worldwide. Woo Tae-hee, the CEO & President of Hyosung Heavy Industries stated, "Hyosung Heavy Industries is dedicated to becoming a global leader in energy solutions, and this collaboration will further solidify our market positions in the energy storage sector. We will closely collaborate with REPT BATTERO to deliver innovative products and services to global customers." Feng Ting, the CEO & President of REPT BATTERO remarked, "This signing marks a significant breakthrough in market synergy between Chinese and South Korean energy storage enterprises. As a global leading battery technology supplier, REPT BATTERO's high-efficiency energy storage batteries complement Hyosung Heavy Industries' deep expertise in the global power industry. Through deep cooperation, the two sides will provide professional products and services to more overseas customers." REPT BATTRO and Hyosung Heavy Industries affirmed their commitment to building upon this strategic partnership to strengthen collaboration in international markets, collectively tackle climate change challenges, and contribute Chinese and Korean insights and solutions to the global energy transition. About Hyosung Heavy Industries Hyosung Heavy Industries, founded in 1977, is a leading Korean company recognized for its global competitiveness in high- and ultra-high-voltage power equipment and energy infrastructure. Hyosung commands the No.1 market share for power transformers in Korea, holds approximately 40% share in the domestic low-voltage motor market, and has accumulated more than KRW 10 trillion in circuit breaker salesboth locally and globally. In Europe, Hyosung leads the 400kV transformer market, especially in Norway with over 80% market share. With decades of EPC experience and strong system engineering capabilities, Hyosung Heavy Industries supplies high-reliability power systems to the Middle East, Southeast Asia, the Americas, and Europe. By addressing global trends toward decarbonization, decentralization, and digitalization in the energy sector, the company is positioning itself as a key enabler of sustainable, global energy transformation. View original content to download multimedia: SOURCE REPT BATTERO Energy Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Korea Herald
19-05-2025
- Automotive
- Korea Herald
Hyosung Heavy Industries secures $60m transformer deal with Scottish Power
Hyosung Heavy Industries, a South Korean company specializing in power and industrial systems and a key affiliate of Hyosung Group, is rapidly expanding its presence in the European power equipment market. The company said Monday that it signed an 85 billion won ($60.8 million) contract with Scotland's transmission company, Scottish Power, to supply 400 kilovolt, ultra-high voltage transformers. These units will support the transmission of wind-generated electricity from onshore and offshore sites to urban areas in Scotland. The deal strengthens Hyosung's leadership in the UK, where it has held the top market share for ultra-high voltage transformers since 2022. Scotland, with its rich wind resources, is a hub for renewable energy and aims to reach net-zero carbon emissions by 2045, prompting major investments in energy infrastructure. Hyosung is also expanding its reach across Western Europe. The company recently became the first Korean manufacturer to sign a long-term transformer supply agreement with a German transmission firm. It has also secured repeat orders in France and new contracts in Spain. 'Our continued success in Europe is the result of our technological capabilities and customer-tailored solution strategies,' said Hyosung Group Chair Cho Hyun-joon. 'We will solidify our position as a core power equipment supplier in the global market, aligned with the growth of the AI industry.' As of the first quarter of this year, Hyosung's total order backlog stands at approximately 10 trillion won, with major projects underway in Europe, North America and beyond.
